18 December 2017
Measuring the return from pharmaceutical innovation 2017
The pharmaceutical industry continues to face an extremely challenging research and development (R&D) environment and has yet to turn a corner in terms of its R&D value proposition. Despite this, the Deloitte UK's report presents an optimistic road ahead for R&D and business leaders, exploring the emerging technologies that have the potential to dramatically transform the productivity and efficiency by which drugs are discovered, developed, and brought to patients.
Key findings for top 12 large-cap biopharma
How are biopharma R&D returns faring?
Other key findings
How digital technology is transforming the future of R&D
Despite many challenges with biopharma R&D, there are numerous examples of innovation that demonstrate pharma’s resilience and optimism about the future—from the approval of numerous immunotherapies to the first ever approvals of chimeric antigen receptor T cell (CAR-T) therapies this year.
Furthermore, there are a range of advanced technologies that have the potential to transform R&D across the entire value chain. Biopharma companies are just starting to experiment with these technologies, and early adopters will reap the rewards of a much more efficient R&D process, improving both the quality of assets and the time and cost it takes to get them to market.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024